Gilead’s stock price has overreacted to negative guidance regarding HCV and the threat of competition in HIV.
The value of Gilead’s HIV franchise and other products supports the current valuation, which means investors get the HCV franchise and non-HIV pipeline optionality for free.
HCV revenue going forward is expected to fall dramatically, but it will continue to generate revenue, earnings and cash flow. It is worth significantly more than zero.
